Home
EXEL
EXEL News

Latest Exelixis Inc. (EXEL) News on April 19, 2025

High Growth Tech Stocks To Watch In The US April 2025

Simply Wall St.

2 days ago

High Growth Tech Stocks To Watch In The US April 2025

Why Exelixis (EXEL) is a Top Momentum Stock for the Long-Term

Zacks

3 days ago

Why Exelixis (EXEL) is a Top Momentum Stock for the Long-Term

Argus Research

4 days ago

EXEL: Raising target price to $40.00

Will Exelixis (EXEL) Beat Estimates Again in Its Next Earnings Report?

Zacks

8 days ago

Will Exelixis (EXEL) Beat Estimates Again in Its Next Earnings Report?

Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio

Zacks

8 days ago

Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio

Argus Research

11 days ago

EXEL: Lowering target price to $37.00

Why Exelixis (EXEL) is a Top Value Stock for the Long-Term

Zacks

11 days ago

Why Exelixis (EXEL) is a Top Value Stock for the Long-Term

The Smartest Biotech Stocks to Buy With $50

Motley Fool

16 days ago

The Smartest Biotech Stocks to Buy With $50

Biotech Stock Roundup: CORT Up on Study Data, Updates From AXSM, BMY, EXEL & More

Zacks

17 days ago

Biotech Stock Roundup: CORT Up on Study Data, Updates From AXSM, BMY, EXEL & More

Is Exelixis, Inc. (EXEL) The Most Profitable Biotech Stock To Buy Right Now?

Insider Monkey

17 days ago

Is Exelixis, Inc. (EXEL) The Most Profitable Biotech Stock To Buy Right Now?

Argus Research

18 days ago

EXEL: Lowering target price to $40.00

FDA Expands Exelixis Cabometyx Label for Neuroendocrine Tumors

Zacks

23 days ago

FDA Expands Exelixis Cabometyx Label for Neuroendocrine Tumors

Exelixis’ cabozantinib approval ‘certainly positive,’ says Citi

TipRanks

23 days ago

Exelixis’ cabozantinib approval ‘certainly positive,’ says Citi

Exelixis to present positive preclinical data across pipeline portfolio at AACR

TipRanks

24 days ago

Exelixis to present positive preclinical data across pipeline portfolio at AACR

Exelixis Stock Rises 13.3% Year to Date: Buy, Sell or Hold?

Zacks

24 days ago

Exelixis Stock Rises 13.3% Year to Date: Buy, Sell or Hold?

Exelixis (NasdaqGS:EXEL) Celebrates FDA Approval For Expanded CABOMETYX® Use In Treating NET

Simply Wall St.

24 days ago

Exelixis (NasdaqGS:EXEL) Celebrates FDA Approval For Expanded CABOMETYX® Use In Treating NET

MT Newswires

24 days ago

Exelixis Gets FDA Approval for Drug Treating Patients With Previously Treated Advanced Neuroendocrine Tumors

Here's Why Exelixis (EXEL) is a Strong Growth Stock

Zacks

24 days ago

Here's Why Exelixis (EXEL) is a Strong Growth Stock

Exelixis Announces U.S. FDA Approval of CABOMETYX® (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors

Business Wire

24 days ago

Exelixis Announces U.S. FDA Approval of CABOMETYX® (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors

Argus Research

25 days ago

EXEL: Raising target price to $41.00

Exelixis to Present Positive Preclinical Data Across Its Pipeline Portfolio for Advanced Cancers at AACR 2025

Business Wire

25 days ago

Exelixis to Present Positive Preclinical Data Across Its Pipeline Portfolio for Advanced Cancers at AACR 2025

Biotech Leader Exelixis Eyes Buy Point In Monday's Stock Market Rally

Investor's Business Daily

a month ago

Biotech Leader Exelixis Eyes Buy Point In Monday's Stock Market Rally

Exact Sciences (EXAS) Down 10.6% Since Last Earnings Report: Can It Rebound?

Zacks

a month ago

Exact Sciences (EXAS) Down 10.6% Since Last Earnings Report: Can It Rebound?

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

Zacks

a month ago

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

Exelixis Growth Continues with Big Money Boosts

FX Empire

a month ago

Exelixis Growth Continues with Big Money Boosts

Exelixis, Inc. (EXEL): Among the Best Biotech Stocks to Buy According to Billionaires

Insider Monkey

a month ago

Exelixis, Inc. (EXEL): Among the Best Biotech Stocks to Buy According to Billionaires

Exelixis (EXEL) Up 13.4% Since Last Earnings Report: Can It Continue?

Zacks

a month ago

Exelixis (EXEL) Up 13.4% Since Last Earnings Report: Can It Continue?

MT Newswires

a month ago

RBC Raises Price Target on Exelixis to $40 From $38, Keeps Outperform Rating

EXEL vs. ARGX: Which Stock Should Value Investors Buy Now?

Zacks

a month ago

EXEL vs. ARGX: Which Stock Should Value Investors Buy Now?

Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick

Zacks

a month ago

Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick

Argus Research

2 months ago

EXEL: Raising target price to $42.00

Why This 1 Value Stock Could Be a Great Addition to Your Portfolio

Zacks

2 months ago

Why This 1 Value Stock Could Be a Great Addition to Your Portfolio

Exploring 3 High Growth Tech Stocks In The US Market

Simply Wall St.

2 months ago

Exploring 3 High Growth Tech Stocks In The US Market

Is Exelixis, Inc. (EXEL) The Best Immunology Stock To Buy Now?

Insider Monkey

2 months ago

Is Exelixis, Inc. (EXEL) The Best Immunology Stock To Buy Now?

Exelixis focuses on future growth despite COSMIC-313 trial challenges

Pharmaceutical Technology

2 months ago

Exelixis focuses on future growth despite COSMIC-313 trial challenges

Zacks.com featured highlights Gilead Sciences, Exelixis, Synchrony Financial and Molson Coors

Zacks

2 months ago

Zacks.com featured highlights Gilead Sciences, Exelixis, Synchrony Financial and Molson Coors

Argus Research

2 months ago

EXEL: Raising target price to $40.00

Exelixis to Webcast Fireside Chats at Upcoming Investor Conferences in March

Business Wire

2 months ago

Exelixis to Webcast Fireside Chats at Upcoming Investor Conferences in March

Analysts Give The Green Light To Two Stocks With Brighter Outlook Than Even Nvidia

Investor's Business Daily

2 months ago

Analysts Give The Green Light To Two Stocks With Brighter Outlook Than Even Nvidia

EXEL or TECH: Which Is the Better Value Stock Right Now?

Zacks

2 months ago

EXEL or TECH: Which Is the Better Value Stock Right Now?

MT Newswires

2 months ago

Wells Fargo Downgrades Exelixis to Equalweight From Overweight, Price Target is $36

Exelixis, Inc. (EXEL): Among Renaissance Technologies Portfolio’s Top Stock Picks

Insider Monkey

2 months ago

Exelixis, Inc. (EXEL): Among Renaissance Technologies Portfolio’s Top Stock Picks

Why Exelixis Stock Trounced the Market on Thursday

Motley Fool

2 months ago

Why Exelixis Stock Trounced the Market on Thursday

Why Is Cancer-Focused Exelixis Stock Trading Higher On Friday?

Benzinga

2 months ago

Why Is Cancer-Focused Exelixis Stock Trading Higher On Friday?

Exelixis' (NASDAQ:EXEL) Earnings May Just Be The Starting Point

Simply Wall St.

2 months ago

Exelixis' (NASDAQ:EXEL) Earnings May Just Be The Starting Point

MT Newswires

2 months ago

Exelixis Board Authorizes Additional Share Buyback Program of Up To $500 Million; Shares Advance After Hours

Exelixis Announces a Newly Authorized $500 Million Stock Repurchase Program

Business Wire

2 months ago

Exelixis Announces a Newly Authorized $500 Million Stock Repurchase Program

Is Exelixis (EXEL) a Solid Growth Stock? 3 Reasons to Think "Yes"

Zacks

2 months ago

Is Exelixis (EXEL) a Solid Growth Stock? 3 Reasons to Think "Yes"

Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick

Zacks

2 months ago

Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick

MT Newswires

2 months ago

Exelixis Insider Sold Shares Worth $1,541,343, According to a Recent SEC Filing

Argus Research

2 months ago

EXEL: Raising target price to $37.00

Exelixis Gains 6.7% Post Q4 Earnings: Is This the Right Time to Buy?

Zacks

2 months ago

Exelixis Gains 6.7% Post Q4 Earnings: Is This the Right Time to Buy?

International Markets and Exelixis (EXEL): A Deep Dive for Investors

Zacks

2 months ago

International Markets and Exelixis (EXEL): A Deep Dive for Investors

Five-year results see Exelixis’ RCC therapy extending overall survival

Clinical Trials Arena

2 months ago

Five-year results see Exelixis’ RCC therapy extending overall survival

Exelixis Full Year 2024 Earnings: EPS Beats Expectations

Simply Wall St.

2 months ago

Exelixis Full Year 2024 Earnings: EPS Beats Expectations

Exelixis Announces Final Five-Year Follow-up Results from CheckMate -9ER Trial Evaluating CABOMETYX® (cabozantinib) in Combination with Opdivo® (nivolumab) in Patients with Advanced Kidney Cancer at ASCO GU 2025

Business Wire

2 months ago

Exelixis Announces Final Five-Year Follow-up Results from CheckMate -9ER Trial Evaluating CABOMETYX® (cabozantinib) in Combination with Opdivo® (nivolumab) in Patients with Advanced Kidney Cancer at ASCO GU 2025

Exelixis (EXEL) is a Top-Ranked Value Stock: Should You Buy?

Zacks

2 months ago

Exelixis (EXEL) is a Top-Ranked Value Stock: Should You Buy?

Exelixis to Participate in the Citi 2025 Virtual Oncology Leadership Summit

Business Wire

2 months ago

Exelixis to Participate in the Citi 2025 Virtual Oncology Leadership Summit

EXEL Tops Q4 Earnings and Sales, Cabometyx Label Expansion in Focus

Zacks

2 months ago

EXEL Tops Q4 Earnings and Sales, Cabometyx Label Expansion in Focus

Exelixis Inc (EXEL) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ...

GuruFocus.com

2 months ago

Exelixis Inc (EXEL) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ...

Exelixis (EXEL) Q4 2024 Earnings Call Transcript

Motley Fool

2 months ago

Exelixis (EXEL) Q4 2024 Earnings Call Transcript

Exelixis (EXEL) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

Zacks

2 months ago

Exelixis (EXEL) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

Exelixis (EXEL) Q4 Earnings and Revenues Top Estimates

Zacks

2 months ago

Exelixis (EXEL) Q4 Earnings and Revenues Top Estimates

MT Newswires

2 months ago

Exelixis' Q4 Non-GAAP Earnings, Revenue Rise

Associated Press Finance

2 months ago

Exelixis: Q4 Earnings Snapshot

Exelixis Announces Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Corporate Update

Business Wire

2 months ago

Exelixis Announces Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Corporate Update

2 Stocks to Buy With Less Than $40

Motley Fool

2 months ago

2 Stocks to Buy With Less Than $40

The 10 best stocks of the last decade

Quartz

2 months ago

The 10 best stocks of the last decade

Zacks.com featured highlights include Pilgrim's Pride, Exelixis, Synchrony and United Airlines

Zacks

2 months ago

Zacks.com featured highlights include Pilgrim's Pride, Exelixis, Synchrony and United Airlines

EXEL or TECH: Which Is the Better Value Stock Right Now?

Zacks

2 months ago

EXEL or TECH: Which Is the Better Value Stock Right Now?

Alnylam Pharmaceuticals (ALNY) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Zacks

2 months ago

Alnylam Pharmaceuticals (ALNY) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Curious about Exelixis (EXEL) Q4 Performance? Explore Wall Street Estimates for Key Metrics

Zacks

2 months ago

Curious about Exelixis (EXEL) Q4 Performance? Explore Wall Street Estimates for Key Metrics

Argus Research

2 months ago

EXEL: What does Argus have to say about EXEL?

Exploring High Growth Tech Stocks in February 2025

Simply Wall St.

3 months ago

Exploring High Growth Tech Stocks in February 2025

Here's Why Exelixis (EXEL) is a Strong Value Stock

Zacks

3 months ago

Here's Why Exelixis (EXEL) is a Strong Value Stock

Repligen (RGEN) Surges 3.7%: Is This an Indication of Further Gains?

Zacks

3 months ago

Repligen (RGEN) Surges 3.7%: Is This an Indication of Further Gains?

Argus Research

3 months ago

EXEL: Rating increased to a BUY

Exelixis to Release Fourth Quarter and Full Year 2024 Financial Results on Tuesday, February 11, 2025

Business Wire

3 months ago

Exelixis to Release Fourth Quarter and Full Year 2024 Financial Results on Tuesday, February 11, 2025

Exelixis (EXEL) Earnings Expected to Grow: Should You Buy?

Zacks

3 months ago

Exelixis (EXEL) Earnings Expected to Grow: Should You Buy?

Exelixis Stock Falls as Oppenheimer Downgrades Rating to Perform

Zacks

3 months ago

Exelixis Stock Falls as Oppenheimer Downgrades Rating to Perform

MT Newswires

3 months ago

Truist Lifts Price Target on Exelixis to $43 From $42, Keeps Buy Rating

MT Newswires

3 months ago

Morgan Stanley Upgrades Exelixis to Overweight From Equalweight, Raises Price Target to $40 From $30

Exelixis Announces Encouraging Results from Phase 1b/2 STELLAR-001 Trial Evaluating Zanzalintinib Alone or in Combination with an Immune Checkpoint Inhibitor in Metastatic Colorectal Cancer at ASCO GI 2025

Business Wire

3 months ago

Exelixis Announces Encouraging Results from Phase 1b/2 STELLAR-001 Trial Evaluating Zanzalintinib Alone or in Combination with an Immune Checkpoint Inhibitor in Metastatic Colorectal Cancer at ASCO GI 2025

MT Newswires

3 months ago

Exelixis Reports Results on Drug Study to Treat Advanced Gastrointestinal Neuroendocrine Tumors

Exelixis Announces Results from Subgroup Analysis of Phase 3 CABINET Pivotal Study Evaluating Cabozantinib in Advanced Gastrointestinal Neuroendocrine Tumors Presented at ASCO GI 2025

Business Wire

3 months ago

Exelixis Announces Results from Subgroup Analysis of Phase 3 CABINET Pivotal Study Evaluating Cabozantinib in Advanced Gastrointestinal Neuroendocrine Tumors Presented at ASCO GI 2025

Exelixis Stock Faces a Reality Check: Will It Hit $41 or Drop to $33?

GuruFocus.com

3 months ago

Exelixis Stock Faces a Reality Check: Will It Hit $41 or Drop to $33?

Exelixis Stock Falls as Oppenheimer Downgrades Over Drug Differentiation Concerns

GuruFocus.com

3 months ago

Exelixis Stock Falls as Oppenheimer Downgrades Over Drug Differentiation Concerns

MT Newswires

3 months ago

Oppenheimer Downgrades Exelixis to Perform From Outperform, Adjusts Price Target to $33 From $41

Revenues, Treatment Pipeline Driving Exelixis Higher

FX Empire

3 months ago

Revenues, Treatment Pipeline Driving Exelixis Higher

Argus Research

3 months ago

EXEL: Raising target price to $38.00

EXEL vs. TECH: Which Stock Is the Better Value Option?

Zacks

3 months ago

EXEL vs. TECH: Which Stock Is the Better Value Option?

What Makes Exelixis (EXEL) an Investment Bet?

Insider Monkey

3 months ago

What Makes Exelixis (EXEL) an Investment Bet?

4 PEG-Based Value Stocks to Neutralize Trump 2.0-Led Market Volatility

Zacks

3 months ago

4 PEG-Based Value Stocks to Neutralize Trump 2.0-Led Market Volatility

Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio

Zacks

3 months ago

Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio

Should You Be Adding Exelixis (NASDAQ:EXEL) To Your Watchlist Today?

Simply Wall St.

3 months ago

Should You Be Adding Exelixis (NASDAQ:EXEL) To Your Watchlist Today?

MT Newswires

3 months ago

William O'Neil Initiates Exelixis at Buy

MT Newswires

3 months ago

Oppenheimer Adjusts Price Target on Exelixis to $41 From $38, Maintains Outperform Rating

BeiGene Stock Meets 80-Plus RS Rating Benchmark

Investor's Business Daily

3 months ago

BeiGene Stock Meets 80-Plus RS Rating Benchmark

MT Newswires

3 months ago

Truist Raises Price Target on Exelixis to $42 From $38, Maintains Buy Rating

Zacks Industry Outlook Highlights Incyte, BioMarin, Exelixis, Halozyme and Blueprint Medicines

Zacks

3 months ago

Zacks Industry Outlook Highlights Incyte, BioMarin, Exelixis, Halozyme and Blueprint Medicines

Share on Social Networks: